title: Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.
abstract: BACKGROUND
  HCV protease inhibitors (PIs) boceprevir and telaprevir in combination with PEG-Interferon alfa and Ribavirin (P/R) is the new standard of care in the treatment of chronic HCV genotype 1 (GT1) infection. However, not every HCV GT1 infected patient is eligible for P/R/PI therapy. Furthermore phase III studies did not necessarily reflect real world as patients with advanced liver disease or comorbidities were underrepresented. The aim of our study was to analyze the eligibility and safety of P/R/PI treatment in a real world setting of a tertiary referral center.
  
  
  METHODS
  All consecutive HCV GT1 infected patients who were referred to our hepatitis treatment unit between June and November 2011 were included. Patients were evaluated for P/R/PI according to their individual risk/benefit ratio based on 4 factors: Treatment-associated safety concerns, chance for SVR, treatment urgency and nonmedical patient related reasons. On treatment data were analyzed until week 12.
  
  
  RESULTS
  208 patients were included (F3/F4 64%, mean platelet count 169/nl, 40% treatment-naïve). Treatment was not initiated in 103 patients most frequently due to safety concerns. 19 patients were treated in phase II/III trials or by local centers and a triple therapy concept was initiated at our unit in 86 patients. Hospitalization was required in 16 patients; one patient died due to a gastrointestinal infection possibly related to treatment. A platelet count of <110/nl was associated with hospitalization as well as treatment failure. Overall, 128 patients were either not eligible for therapy or experienced a treatment failure at week 12.
  
  
  CONCLUSIONS
  P/R/PI therapies are complex, time-consuming and sometimes dangerous in a real world setting, especially in patients with advanced liver disease. A careful patient selection plays a crucial role to improve safety of PI based therapies. A significant number of patients are not eligible for P/R/PI, emphasizing the need for alternative therapeutic options.
authors: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
authors: Benjamin
authors: B
authors: Maasoumy
authors: Kerstin
authors: K
authors: Port
authors: Antoaneta Angelova
authors: AA
authors: Markova
authors: Beatriz Calle
authors: BC
authors: Serrano
authors: Magdalena
authors: M
authors: Rogalska-Taranta
authors: Lisa
authors: L
authors: Sollik
authors: Carola
authors: C
authors: Mix
authors: Janina
authors: J
authors: Kirschner
authors: Michael P
authors: MP
authors: Manns
authors: Heiner
authors: H
authors: Wedemeyer
authors: Markus
authors: M
authors: Cornberg
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004608:Eligibility Determination; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D009842:Oligopeptides / Q000627:therapeutic use*; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; C100416:peginterferon alfa-2a
references: N Engl J Med. 1998 Nov 19;339(21):1493-9
references: 9819447
references: Hepatology. 2005 Jan;41(1):48-54
references: 15690481
references: Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):58-67
references: 18973847
references: J Hepatol. 2011 Mar;54(3):415-21
references: 21112657
references: N Engl J Med. 2011 Mar 31;364(13):1195-206
references: 21449783
references: Gut. 2012 Dec;61(12):1647-52
references: 22936671
references: Z Gastroenterol. 2010 Feb;48(2):289-351
references: 20119896
references: Gastroenterology. 2012 Sep;143(3):608-618.e5
references: 22626609
references: N Engl J Med. 2011 Mar 31;364(13):1207-17
references: 21449784
references: J Hepatol. 2011 Aug;55(2):245-64
references: 21371579
references: Liver Int. 2011 Jul;31 Suppl 2:30-60
references: 21651702
references: N Engl J Med. 2011 Jun 23;364(25):2405-16
references: 21696307
references: Clin Microbiol Infect. 2011 Feb;17(2):107-15
references: 21091831
references: Gastroenterology. 2012 Oct;143(4):974-85.e14
references: 22863764
references: Ann Intern Med. 2007 Nov 20;147(10):677-84
references: 18025443
references: Gut. 2006 Sep;55(9):1350-9
references: 16905701
references: N Engl J Med. 2012 Jan 19;366(3):216-24
references: 22256805
references: N Engl J Med. 2011 Jun 23;364(25):2417-28
references: 21696308